Research News on Chemotherapy
-
Tykerb and Xeloda Seem to Shrink HER2-Positive Breast Cancer That’s Spread to Brain
A very small, very early study suggests the combination of Tykerb and Xeloda shrinks HER2-positive breast cancer lesions in the brain without radiation.
-
Use of Anthracyclines to Treat Breast Cancer Has Gone Down
A study has found that after 2005, there was a large increase in taxane chemotherapy and a decrease in anthracycline chemotherapy to treat breast cancer in the United States.
-
Chemo During Pregnancy Appears Safe for Mother and Child
A study supports other research that suggests chemotherapy during pregnancy doesn't have harmful effects on the baby.
-
Research Suggests How Metastatic Cancer Becomes Resistant to Chemotherapy
A very early study on cancer cells in petri dishes in the lab has found that a type of cell called a fibroblast also is damaged by chemotherapy. Damaged fibroblasts make a protein called WNT16B that may help metastatic cancer cells become resistant to chemotherapy and grow.
-
Cymbalta Helps Ease Neuropathy Caused by Chemo
A study has found that most people with peripheral neuropathy got some relief from the antidepressant medicine Cymbalta.
-
MRI Better at Assessing Results of Chemo Before Surgery
Research shows that breast MRI before surgery is better at assessing how well a cancer responds to neoadjuvant treatment compared to more traditional assessment measures such as a physical exam, mammogram, or ultrasound.
-
T-DM1 Works Better on Advanced-Stage, HER2-Positive Cancer Than Standard Meds
A study found that women diagnosed with advanced-stage, HER2-positive breast cancer that had stopped responding to a standard regimen lived longer without the cancer growing when they got the experimental medicine T-DM1 compared to women who got a different regimen.
-
New Doxorubicin Formula May Be Safer for Heart Than Traditional Formulas
A small study suggests that a new formulation of the chemotherapy medicine doxorubicin may be safer for the heart than traditional formulations.
-
Afinitor Before Surgery Doesn’t Help Treat HER2-Negative Breast Cancer
Research has found that adding Afinitor to paclitaxel didn't improve the response to neoadjuvant treatment with paclitaxel in women diagnosed with advanced-stage, HER2-negative breast cancer.
-
Zometa Seems to Reduce Recurrence Risk of Early-Stage Breast Cancer
A study suggests that Zometa after surgery may reduce the risk of recurrence and improve overall survival in postmenopausal women diagnosed with early-stage breast cancer.
